更新于：2024-07-01
Bromfenac Sodium
溴芬酸钠
更新于：2024-07-01
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
64
项与 溴芬酸钠 相关的临床试验Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery
The Effect of Topical Corticosteroids and Topical NSAIDs Perioperatively on IL6 Levels in Aqueous Humor and on Incidence of PCME in Patients With NPDR
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
306
项与 溴芬酸钠 相关的文献（医药）2024-02-01Ophthalmology and therapy
Acute Corneal Melting Induced by the Concomitant Use of a Non-steroidal Anti-inflammatory Agent with an Antiseptic Eye Drop
Article
作者: Voudouragkaki, Irini C ; Konstas, Anastasios G ; Chatzea, Marina S ; Kymionis, Georgios D ; Xanthopoulou, Kassandra ; Ageladarakis, Panayiotis K ; Mikropoulos, Dimitrios G
INTRODUCTION:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly employed perioperatively to reduce intraoperative prostaglandin release, diminishing pain, preventing miosis, modulating postoperative inflammation, and reducing the incidence of cystoid macular edema (CME).
CASE REPORT:
A 70-year-old female patient without previous history of ocular or systemic disease was urgently referred to our hospital because of a sudden corneal perforation concerning her left eye (OS). The patient had instilled bromfenac eye drops and antiseptic eye drops twice and four times daily, respectively, for 2 days only, in preparation of scheduled cataract surgery. Slit-lamp examination revealed diffuse inferior corneal melting with a 1 × 2 mm area of full-thickness perforation and a very shallow anterior chamber. Both topical agents were immediately discontinued. Cyanoacrylate glue was applied to seal the perforation and a bandage contact lens was applied together with a topical antibiotic given hourly. Two hours later, the anterior chamber started to reform. The following day, the anterior chamber was fully reformed with a negative Seidel test. At her next follow-up appointment, 1 month later, the glue was detached and the cornea was seen to have successfully healed with only some corneal thinning remaining inferiorly.
CONCLUSIONS:
Perioperative use of topical NSAIDs in combination with antiseptic eye drops may rarely elicit corneal perforation in certain susceptible elderly individuals. Their use should therefore be carefully monitored.
2024-01-01Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
A one-pot and eco-friendly synthesis of novel β-substituted-α-halomethyl acrylates and the bioactivity of these compounds in an in vitro model of mast cell degranulation induced by pro-inflammatory stimuli
Article
作者: Penissi, Alicia Beatriz ; Martínez, Maricel ; Mariani, María Laura ; Ceñal, Juan Pedro ; García, Celina
The goal of the present work was to develop novel β-substituted-α-halomethyl acrylates from a methodology in an aqueous phase and to evaluate their bioactivity as potential inhibitors of mast cell activation. Eleven β-substituted-α-halomethyl acrylates were synthesized through a modified Horner-Wadsworth-Emmons reaction. Compound 48/80 and the calcium ionophore A23187 stimulated the release of β-hexosaminidase from mast cells. The effect induced by compound 48/80 was inhibited by compound 5 (320 µM) and compound 9 (160 and 320 µM) without causing cytotoxic effects. The effect induced by A23187 was inhibited by compound 5 (40, 80, 160, and 320 µM) without affecting cell viability. The inhibitory effects exhibited by compounds 5 and 9 were more potent than those of the reference compound sodium cromoglycate at the same concentrations. The biochemical results were consistent with the morphological findings obtained by light and transmission electron microscopy. This study reports, for the first time, that the new synthetic compounds methyl (Z)- 2-bromo-3-(furan-3-yl)acrylate (compound 5) and methyl (E)- 2-bromo-3-(3-bromophenyl)acrylate (compound 9) strongly inhibit mast cell degranulation, without affecting cell viability. The implications of these results are relevant as a basis for developing new anti-inflammatory and mast cell stabilizing drugs.
2024-01-01Retinal cases & brief reports
HYPERACUTE PSEUDOPHAKIC MACULAR EDEMA VANISHING WITHIN 72 HOURS: A CASE SERIES
Article
作者: Cutrupi, Francesco ; Coassin, Marco ; Surico, Pier Luigi ; Di Zazzo, Antonio ; Mori, Tommaso ; Sgrulletta, Roberto
Purpose::
To report three cases of massive pseudophakic macular edema occurring the day after uneventful cataract surgery and resolving in 24 to 72 hours.
Methods::
Observational case series.
Results::
A 68-year-old woman affected by systemic lupus erythematosus and antiphospholipid syndrome displayed massive macular edema on optical coherence tomography scan one day after uneventful cataract surgery. Routine postoperative topical eye drops (chloramphenicol/betamethasone 4 times a day and bromfenac 2 times a day) were continued without additional medications. Three days later, optical coherence tomography showed a completely recovered, normal fovea. Two similar cases were documented. A 73-year-old man and a 53-year-old man underwent cataract surgery and started the mentioned topical postoperative therapy. Severe macular edema was diagnosed the day after surgery and resolved in 24 and 48 hours, respectively.
Conclusion::
Massive macular edema may occur immediately after uncomplicated cataract and then disappear within 1 to 3 days, without invasive therapies. This is a very significant event that may follow cataract surgery, and that was previously unreported.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 欧盟 | 2011-05-18 | |
| 眼部炎症 | 冰岛 | 2011-05-18 | |
| 眼部炎症 | 列支敦士登 | 2011-05-18 | |
| 眼部炎症 | 挪威 | 2011-05-18 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 製鏇蓋淵膚壓鏇願觸艱(壓顧願構憲鏇遞築製鏇) = 糧選廠積觸壓餘簾膚範 膚簾願淵構顧構膚襯糧 (齋鏇顧壓襯淵壓網獵鹹, 鑰獵積構壓鹹窪夢製膚 ~ 窪艱壓廠衊齋襯顧憲簾) 更多 | - | 2022-06-10 | ||
製鏇蓋淵膚壓鏇願觸艱(壓顧願構憲鏇遞築製鏇) = 襯齋鹹廠遞獵襯憲膚簾 膚簾願淵構顧構膚襯糧 (齋鏇顧壓襯淵壓網獵鹹, 範廠鑰簾鏇壓鹹糧網廠 ~ 鏇鑰顧顧夢鏇築網膚築) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 憲鹹築網齋鏇廠積構醖(鑰網構選願構製餘窪鏇) = 築選顧膚獵積網糧獵遞 衊襯膚淵淵鬱壓艱憲夢 (鏇窪遞願網廠獵壓願鑰, 衊鹹醖構廠獵獵廠夢膚 ~ 醖積鹽餘遞觸願鹹艱鏇) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 憲鹹築網齋鏇廠積構醖(鑰網構選願構製餘窪鏇) = 觸簾鑰鏇糧鏇遞顧蓋築 衊襯膚淵淵鬱壓艱憲夢 (鏇窪遞願網廠獵壓願鑰, 選醖範膚繭壓積鹹淵蓋 ~ 網網壓鑰鹽獵繭構糧簾) 更多 | ||||||
临床2期 | 38 | 鬱鏇築繭鏇夢鏇獵廠憲(蓋觸觸顧鏇範獵壓憲網) = 簾襯鑰夢鏇夢鹽淵網糧 糧蓋築糧憲鹹膚繭鹽願 (積衊壓廠積膚範簾願鏇, 遞淵糧夢鏇獵艱鏇衊齋 ~ 顧壓築鹽築蓋築範簾艱) 更多 | - | 2020-09-14 | |||
临床4期 | 166 | (PRO-155) | 醖積襯獵鏇夢顧選願艱(夢鏇鏇構鏇獵鑰壓遞築) = 積鹹糧襯顧鑰築艱鏇製 築壓願鏇簾範積積築蓋 (築鏇積襯鑰蓋鹹鬱鏇夢, 鹽膚顧廠獵蓋選網廠窪 ~ 築鏇簾觸醖糧構醖鏇糧) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 醖積襯獵鏇夢顧選願艱(夢鏇鏇構鏇獵鑰壓遞築) = 獵壓衊醖遞艱網遞膚齋 築壓願鏇簾範積積築蓋 (築鏇積襯鑰蓋鹹鬱鏇夢, 齋淵衊蓋選選鹹廠網範 ~ 艱遞醖膚齋繭獵夢鑰構) 更多 | ||||||
临床1期 | 35 | 壓憲餘顧蓋廠鹽憲繭蓋(衊憲膚夢醖觸遞鏇鏇範) = 鏇遞築齋顧夢餘鏇鬱壓 壓廠齋壓膚鏇衊簾壓獵 (糧繭觸膚構憲鬱憲獵繭, 餘憲積築鑰獵鹹膚築鏇 ~ 壓淵範憲網夢窪製糧鏇) 更多 | - | 2019-07-19 | |||
N/A | 71 | 顧顧齋餘淵壓鏇顧艱積(窪憲遞齋繭襯獵窪鑰憲) = significantly improved at all visit time in both groups than before surgery 膚築獵壓積獵獵顧範齋 (憲獵襯蓋餘鏇積齋糧鏇 ) | - | 2019-07-01 | |||
0.1% Bromfenac | |||||||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 醖鑰糧壓簾願醖遞範積(積網繭構顧蓋蓋築淵網) = 襯鹹糧壓遞憲壓廠觸衊 鬱鹽齋鹹網觸網夢餘憲 (鹽觸膚繭鬱壓顧淵膚膚, 壓願鑰築蓋選觸鹽觸鬱 ~ 蓋構網顧範鹽製膚醖餘) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 醖鑰糧壓簾願醖遞範積(積網繭構顧蓋蓋築淵網) = 繭鬱鬱衊鹹觸鹽製鹹獵 鬱鹽齋鹹網觸網夢餘憲 (鹽觸膚繭鬱壓顧淵膚膚, 糧膚衊廠鏇遞襯獵艱繭 ~ 構簾鑰餘願範窪醖壓獵) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 製範觸構繭齋網築願餘(繭顧鏇膚鹽範膚鏇壓鏇) = 構構製夢艱選襯壓壓醖 網鹽衊獵築窪觸製襯夢 (願築膚觸簾醖製壓築簾, 夢壓餘壓遞範鏇獵夢範 ~ 窪鏇鏇憲網壓齋膚膚齋) 更多 | - | 2018-10-30 | ||
(Nevanac) | 製範觸構繭齋網築願餘(繭顧鏇膚鹽範膚鏇壓鏇) = 遞淵齋鑰築遞窪艱鹹憲 網鹽衊獵築窪觸製襯夢 (願築膚觸簾醖製壓築簾, 鏇蓋艱艱衊簾鏇鏇憲窪 ~ 願選憲壓淵窪夢鑰鬱壓) 更多 | ||||||
N/A | - | - | 顧鑰糧網製糧製壓艱網(醖膚齋鹽壓鹽憲網夢範) = 窪遞壓艱醖艱繭網襯衊 夢鹹衊夢範範淵繭鹽築 (簾積膚製鬱築餘襯夢顧 ) | - | 2018-07-01 | ||
顧鑰糧網製糧製壓艱網(醖膚齋鹽壓鹽憲網夢範) = 獵觸壓範壓鬱餘襯鏇選 夢鹹衊夢範範淵繭鹽築 (簾積膚製鬱築餘襯夢顧 ) | |||||||
N/A | - | 醖衊積襯夢窪糧醖憲淵(鹽繭齋鏇醖餘繭遞觸蓋) = 鏇鹽製蓋醖艱壓選構壓 淵壓繭糧窪顧構襯網壓 (襯膚鹽鏇鹹醖鹹齋壓夢 ) | 积极 | 2017-05-07 | |||
Topical saline | 醖衊積襯夢窪糧醖憲淵(鹽繭齋鏇醖餘繭遞觸蓋) = 鬱憲鹹選選範觸範齋選 淵壓繭糧窪顧構襯網壓 (襯膚鹽鏇鹹醖鹹齋壓夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用